Next Vial vs Peak Wellness
Two GLP-1 desks, one scoreboard. We put Next Vial and Peak Wellness head-to-head on the published Brief Score — the same six factors, scored the same way.
Peak Wellness
The verdict
Peak Wellness takes this head-to-head.
Peak Wellness scores 83 to 66 on our six-factor Brief Score — A polished, nationwide wellness brand at a premium price — but without a LegitScript badge to back the sticker.
That doesn't make Next Vial a bad call — it's best for people seeking compounded glp-1 care with legitscript certification and a named pharmacy partner. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Next Vial | Peak Wellness | |
|---|---|---|
| Brief Score | 66/100 (C) | 83/100 (B) |
| Semaglutide | From $250/mo (compounded) | $249/mo |
| Tirzepatide | Not disclosed | $349/mo |
| Coverage | 49 states | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
| On the tracker | Newnew to the tracker, no prior reading | Stableprice stable |
Next Vial: New to the tracker on 1 August 2026. The published line reads From $250/mo (compounded) at our first reading; there is no earlier reading of ours to compare it against yet.
Peak Wellness: $249 sema / $349 tirz nationwide; no accreditation listed.
● Not sold on either?
CoreAge Rx tops the whole ranking at 94/100.
The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.